Stephen Murphy, Co-Founder of Prohibition Partners, chats about the upcoming PSYCH Investor Summit taking place on April 21, 2021.
Similar Posts
Psychedelic Business Roundup- Key Psychedelic Industry Leader Joins The NASDAQ
May 12, 2021- This week’s Psychedelic Business News Round Up’s…
Mendeleyev: Music, Magic, Mushrooms
In the realm where music meets the mystical, few artists embody the fusion of psychedelic exploration and sonic innovation like Mendeleyev.
The Spotlight Round Up Video, April 14th
In this week’s episode of The Spotlight Roundup, we check in with the Fireside Project, the first-ever 24/7 psychedelic peer support line; the State of Oregon forms an advisory board to oversee the implementation of psilocybin use in specialized clinics; and The American Journal of Psychiatry publishes new guidance on how to safety and effectively use Ketamine and Esketamine.
Find Your Inner Healing with Psychedelic Therapy | ATMA CEO Interview
In today’s episode of PSYCBiz, James, the Psychedelic Investor, sits down with David Harder, Co-CEO of ATMA.
ATMA is a company that is primarily focused on training therapists on how to conduct psychedelic therapy.
The company also has plans to launch psilocybin clinical trials, treat depression patients in Canada under the SAP program, and work with Oregon in their legalization of psilocybin therapy.
This interview took place at the Catalyst Summit, a psychedelic conference that David Harder helped organize. This conference saw big names like Paul Stamets attend.
In the conversation, David and James get philosophical and discuss the nature of psychedelics and consciousness. Topics such as the right to try are also discussed.
To learn more about ATMA, visit: https://www.atmajourney.com/
To learn more about Catalyst, visit: https://catalystpresents.ca/
#psychedelics #therapy #magicmushrooms
Mapping the Brain on Psychedelics & the Complexity Science Perspective with Manesh Girn
Psychedelic neuroscientist, Manesh Girm, talks about his research into neuroimaging of the brain while subjected to psychedelic states and more.
Is MindMed Expanding to PSILOCYBIN? (BIG MMED / MMEDF Stock NEWS)
In today’s episode, we will be covering some Massive MindMed news that broke on January 14th that lead me to believe that MindMed might be expanding to psilocybin.
Mindmed stock, MMED on the Canadian NEO market, and MMEDF on the American OTC market led with a press release entitled “MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience”. MindMed revealed that the company has added a scientist named Robert Barrow as their Chief Development Officer.
Tucked away in this news release about a hiring decision is a quote which points to a future MindMed project
And that project will be researching the effects of Psilocybin
So up until now, MindMed has focused all their phase 2 trials on LSD and 18-MC, which is a derivative of Ibogaine, while leaving treating maladies with psilocybin to other companies like Compass Pathways (NASDAQ:CMPS).
So, Barrow is bringing with him to MindMed intimate knowledge about the efficacy of psilocybin in treating MDD, as well as dosing data and regime set up.
MindMed (MMED/MMEDF) has some phase 1 trials looking at the safety of psilocybin in conjunction with the Liechti Lab at the University Hospital Basel
and is also comparing psilocybin to LSD in a phase 1 trial. MindMed also has a licence to test psilocybin. However, MindMed has yet to start a trial specifically looking at psilocybin as a medicine..
So does this mean that MindMed’s hiring decision is related to the company’s plans on expanding their clinical trial pipeline to include a psilocybin treatment, sometime in the future? If that speculation turns out to be true, that decision will further expand MindMed’s potential product pipeline as well as the MindMed stock.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF